Pulmonary thromboembolism in a breast cancer woman receiving anastrozole and prophylactic nadroparin  

一例接受阿那曲唑和预防性那屈肝素治疗的乳腺癌妇女发生肺动脉栓塞(英文)

作　　者：Maria José Molina-Garrido Carmen Guillén-Ponce 

机构地区：[1]Department of Oncology, General University Hospital from Elche, Alicante, Spain

出　　处：《The Chinese-German Journal of Clinical Oncology》2007年第5期507-508,共2页中德临床肿瘤学杂志（英文版）

摘　　要：Hormonal treatment is widely accepted for the adjuvant treatment of breast carcinoma, in order to get a reduction in the synthesis of estrogen or to block estrogen receptors in tumors that are hormone dependent. There are multiple dsk factors that contribute to hypercoagulability in cancer patients. Hormonal therapy and chemotherapy are the main one. Type and stage of malignancy are other dsk factors; so age, immobility and surgery are. The main antineoplastic therapy with definitive hypercoagulable effect is tamoxifen, because it can cause reduction in the concentrations of antithrombin III and protein C. Here, we explain the case of a 75-year-old postmenopausal woman presenting with breast carcinoma who suffered from pulmonary thromboembolism during the treatment with anastrozole although she was taking nadropadn.

关 键 词：阿那曲唑 那屈肝素 治疗 乳腺癌 妇女 肺动脉栓塞 

分 类 号：R737.9[医药卫生—肿瘤]